Patterson S, Flatt P R, Brennan L, Newsholme P, McClenaghan N H
School of Biomedical Sciences, University of Ulster, Coleraine, BT52 1SA, UK.
J Endocrinol. 2006 May;189(2):301-10. doi: 10.1677/joe.1.06537.
Elevated plasma homocysteine has been reported in individuals with diseases of the metabolic syndrome including vascular disease and insulin resistance. As homocysteine exerts detrimental effects on endothelial and neuronal cells, this study investigated effects of acute homocysteine exposure on beta-cell function and insulin secretion using clonal BRIN-BD11 beta-cells. Acute insulin release studies in the presence of various test reagents were performed using monolayers of BRIN-BD11 cells and samples assayed by insulin radioimmunoassay. Cellular glucose metabolism was assessed by nuclear magnetic resonance (NMR) analysis following 60-min exposure of BRIN-BD11 cell monolayers to glucose in either the absence or presence of homocysteine. Homocysteine dose-dependently inhibited insulin release at moderate and stimulatory glucose concentrations. This inhibitory effect was reversible at all but the highest concentration of homocysteine. 13C-glucose NMR demonstrated decreased labelling of glutamate from glucose at positions C2, C3 and C4, indicating that the tricarboxylic acid (TCA) cycle-dependent glucose metabolism was reduced in the presence of homocysteine. Homocysteine also dose-dependently inhibited insulinotropic responses to a range of glucose-dependent secretagogues including nutrients (alanine, arginine, 2-ketoisocaproate), hormones (glucagon-like peptide-1 (7-36)amide, gastric inhibitory polypeptide and cholecystokinin-8), neurotransmitter (carbachol), drug (tolbutamide) as well as a depolarising concentration of KCl or elevated Ca2+. Insulin secretion induced by activation of adenylate cyclase and protein kinase C pathways with forskolin and phorbol 12-myristate 13-acetate were also inhibited by homocysteine. These effects were not associated with any adverse action on cellular insulin content or cell viability, and there was no increase in apoptosis/necrosis following exposure to homocysteine. These data indicate that homocysteine impairs insulin secretion through alterations in beta-cell glucose metabolism and generation of key stimulus-secretion coupling factors. The participation of homocysteine in possible beta-cell demise merits further investigation.
据报道,患有代谢综合征疾病(包括血管疾病和胰岛素抵抗)的个体血浆同型半胱氨酸水平升高。由于同型半胱氨酸对内皮细胞和神经元细胞有有害影响,本研究使用克隆的BRIN-BD11β细胞,研究了急性同型半胱氨酸暴露对β细胞功能和胰岛素分泌的影响。在存在各种测试试剂的情况下,使用BRIN-BD11细胞单层进行急性胰岛素释放研究,并通过胰岛素放射免疫测定法对样品进行检测。在不存在或存在同型半胱氨酸的情况下,将BRIN-BD11细胞单层暴露于葡萄糖60分钟后,通过核磁共振(NMR)分析评估细胞葡萄糖代谢。在中等和刺激性葡萄糖浓度下,同型半胱氨酸剂量依赖性地抑制胰岛素释放。除了最高浓度的同型半胱氨酸外,这种抑制作用在所有浓度下都是可逆的。13C-葡萄糖NMR显示,在C2、C3和C4位置,葡萄糖对谷氨酸的标记减少,表明在存在同型半胱氨酸的情况下,三羧酸(TCA)循环依赖性葡萄糖代谢减少。同型半胱氨酸还剂量依赖性地抑制对一系列葡萄糖依赖性促分泌剂的促胰岛素反应,这些促分泌剂包括营养物质(丙氨酸、精氨酸、2-酮异己酸)、激素(胰高血糖素样肽-1(7-36)酰胺、胃抑制多肽和胆囊收缩素-8)、神经递质(卡巴胆碱)、药物(甲苯磺丁脲)以及去极化浓度的氯化钾或升高的钙离子。用福司可林和佛波醇12-肉豆蔻酸酯13-乙酸酯激活腺苷酸环化酶和蛋白激酶C途径诱导的胰岛素分泌也受到同型半胱氨酸的抑制。这些作用与对细胞胰岛素含量或细胞活力的任何不良作用无关,并且在暴露于同型半胱氨酸后凋亡/坏死没有增加。这些数据表明,同型半胱氨酸通过改变β细胞葡萄糖代谢和关键刺激-分泌偶联因子的产生来损害胰岛素分泌。同型半胱氨酸在可能的β细胞死亡中的作用值得进一步研究。